| Date | Form | Description | Docs | XBRL | Pages |
| 01/18/05 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
51 | |
| 01/18/05 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
59 | |
| 01/18/05 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT |
|
3 | |
| 12/22/03 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
51 | |
| 02/13/03 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
49 | |
| 01/29/03 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT |
|
3 | |
| 01/29/02 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
48 | |
| 02/01/01 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
35 | |
| 01/29/01 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
35 | |
| 01/28/00 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
60 |
Latest News & Events
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
Read More...Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million
Read More...Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock
Read More...